ArticlePharmacoepidemiology and drug safety2025
Development and Application of an Algorithm for Statin-Induced Myopathy Based on Electronic Health Record-Derived Structured Elements.
Article in Pharmacoepidemiology and drug safety, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Development and Application of an Algorithm for Statin-Induced Myopathy Based on Electronic Health Record-Derived Structured Elements.Pharmacoepidemiology and drug safety · 2025Article
- Association of Omeprazole-Related Myopathy With Drug-Drug and Drug-Gene Interactions Involving CYP2C19 and CYP3A4: A Nested Case-Control Study.Pharmacotherapy · 2025Article
- SLCO1B1 Functional Variants, Bilirubin, Statin-Induced Myotoxicity, and Recent Sub-Saharan African Ancestry: A Precision Medicine Health Equity Study.Clinical pharmacology and therapeutics · 2025Article
Corrections and comments
- Update of
Authors and funding
6 authors.
Funding
Abstract
purposeConsidering the non-specific nature of muscle symptoms, studies of statin-induced myopathy (SIM) in electronic health records require accurate algorithms that can reliably identify true statin-causing cases. Prior algorithms were constructed in study populations that preclude broad applicability.
methodsUsing only structured data elements of electronic health records, we developed a two-step algorithm to identify true SIM cases. Step 1 excluded potential cases that were linked to secondary (non-statin) causes. Step 2 required evidence of statin discontinuation to deem remaining potential cases as true. To validate our algorithm, we first randomly chose a subset of statin users with potential SIM. From this subset, we then identified true SIM cases using two different methods: (1) our algorithm and (2) manual chart review. Algorithm performance was assessed by comparing the algorithm-derived SIM cases to those from manual chart review, which was considered the gold standard. Metrics of algorithm performance included sensitivity and specificity. We then applied this algorithm to identify predictors of SIM.
resultsOur algorithm had 76% sensitivity, 77% specificity, and 48% positive predictive value for detecting gold standard cases. Applying our algorithm, we identified 1257 algorithm-derived SIM cases from 5430 potential cases. Pravastatin use was associated with a 2.18 odds (95% confidence interval [CI] 1.39-3.40, p = 0.0007) for SIM compared to lovastatin use after adjusting for prespecified factors. Hypothyroidism had the most dramatic increase in risk (odds ratio 15.65, 95% CI 9.12-26.83, p < 0.0001).
conclusionsWe have produced an efficient, easy-to-apply methodological tool that can improve the quality of future research on SIM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.